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background: Reduced nicotinamide adenine dinucleotide phosphate (NADPH) level is increased in the failing heart and leads to reduced opening 
of the mitochondria ATP-dependent K+ channels (MitoKATP) leading to ionic dysregulation in the mitochondrial environment with subsequent matrix 
contraction and reduced ATP production. Increased opening of MitoKATP improves oxidative phosphorylation by maintaining architecture of the 
inner mitochondrial membrane, preserving the low permeability of the outer membrane to ADP and permitting “efficient” energy transfer between 
mitochondrial and myofibrillar ATPase. Bendavia (MTP-131) is a novel mitochondria targeting peptide that was previously shown to improve LV 
function in dogs with chronic heart failure (HF) and to improve rate of ATP synthesis by mitochondria. The present study tested the hypothesis that 
chronic therapy with Bendavia augments MitoKATP opening in LV myocardium of dogs with chronic HF (LV ejection fraction ~30%).
Methods: Ten dogs with coronary microembolization-induced chronic HF were randomized to 3 months therapy with subcutaneous injections of 
Bendavia (0.5 mg/kg once daily, n=5) or to subcutaneous daily injections of saline (Control, n=5). Fresh LV tissue at the end of 3 months of therapy 
was used to isolate mitochondria. MitoKATP was measured using the thallium-sensitive fluorophore assay kit and expressed in relative fluorescence 
units (RFU) per mg protein. Mitochondria ATP to ADP ratio was measured using the bioluminescent ApoSENSORTM assay kit.
results: Compared to HF Controls, therapy with Bendavia resulted in a significant increase in opening of MitoKATP (1372 ± 112 vs. 2775 ± 254 
RFU/mg protein, p<0.05). Further, Bendavia therapy significantly increased ATP/ADP ratio (0.38 ± 0.04 vs. 1.16 ± 0.15, p<0.05).
conclusions: Long-term therapy with Bendavia augments opening of MitoKATP and increases ATP/ADP ratio in dogs with chronic advanced HF. 
These findings are consistent with the observed improvement of LV function in dogs with advanced HF following long-term therapy with Bendavia.
